Study confirms significant waning of original shingles vaccine over 10 years
The original vaccine against shingles — Zostavax, a live shingles vaccine no longer used in the U.S. — is effective in the first year after vaccination but wanes significantly over the following decade, according to a study by Kaiser Permanente’s Vaccine Study Center published in the journal BMJ.
COVID-19 vaccination was effective in children, adolescents during 2021
A large study of U.S. children and teens who received the Pfizer/BioNTech COVID-19 vaccine finds that it was effective through much of 2021, but waned over time, especially as the omicron variant became dominant in 2022. Teens who received a booster dose regained some protection.
COVID-19 vaccination of mother during pregnancy protects infant, though protection wanes
Being vaccinated against COVID-19 during pregnancy provides protection for the baby through its first several months of life, a Kaiser Permanente analysis finds. Protection was stronger against the delta variant than the more recent omicron variant.
COVID-19 patients did better if they had booster vaccination
A large Kaiser Permanente analysis of COVID-19 patients confirms the value of vaccination, finding higher rates of hospitalization and advanced medical care for COVID-19 patients who were unvaccinated, were vaccinated but not boosted, or who had an additional health condition such as obesity or heart disease.
Study identifies geographic clusters of pregnant women who missed flu shots
A Kaiser Permanente analysis of women who did not get flu shots during their pregnancies found the women clustered in geographic “hot spots.” These women tended to have fewer prenatal medical visits and live in low-income neighborhoods.
Waning potency of pertussis vaccine a significant contributor to recent whooping cough outbreaks
Children who were up to date on their pertussis vaccine schedule were far less likely to develop the disease than those unvaccinated. The risk of vaccinated children becoming ill increased with time since vaccination, suggesting waning effectiveness.
Work by the Division of Research Makes Top JAMA Lists for 2018
The JAMA Network, the publication home for numerous top-tier journals from the American Medical Association, released a list of the “Most Talked About Articles” in each of their various publications for 2018. DOR research appears on four lists.
Eight Weeks or Twelve? Kaiser Permanente Study Shows Shorter Hepatitis C Regimen Effective in Black Patients
A new study shows that a treatment regimen of 8 weeks for hepatitis C may be just as effective as 12 weeks in black patients. The study also showed that more people overall can take advantage of the shorter treatment durations, which has important implications for access given the medication’s high cost.